Haemonetics Corporation

NYSE:HAE Stock Report

Market Cap: US$3.8b

Haemonetics Future Growth

Future criteria checks 4/6

Haemonetics is forecast to grow earnings and revenue by 24.3% and 6% per annum respectively. EPS is expected to grow by 24.8% per annum. Return on equity is forecast to be 28.2% in 3 years.

Key information

24.3%

Earnings growth rate

24.8%

EPS growth rate

Medical Equipment earnings growth17.0%
Revenue growth rate6.0%
Future return on equity28.2%
Analyst coverage

Good

Last updated18 Dec 2024

Recent future growth updates

Recent updates

Investors Interested In Haemonetics Corporation's (NYSE:HAE) Earnings

Dec 06
Investors Interested In Haemonetics Corporation's (NYSE:HAE) Earnings

These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well

Sep 09
These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well

What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E

Aug 14
What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E

Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?

Jul 18
Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?

Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth

Jun 21

Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?

Apr 30
Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?

Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion

Apr 12
Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion

Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate

Mar 07
Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate

Haemonetics Corporation: Improved Performance, Another Bolt-On Deal

Mar 06

The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

Feb 15
The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business

The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Jan 01
The Price Is Right For Haemonetics Corporation (NYSE:HAE)

Haemonetics: Solid Performance Of This Blood Play

Nov 22

Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today

Nov 14
Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today

Is Haemonetics (NYSE:HAE) A Risky Investment?

Oct 24
Is Haemonetics (NYSE:HAE) A Risky Investment?

Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment

Oct 13

Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains

Aug 09

Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

Aug 09
Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors

An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Jul 25
An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Jul 07
Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Apr 06
Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Mar 19
Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?

Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer

Feb 16

Haemonetics: Earnings Rate Of Change Justifies High Multiples

Feb 01

We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Jan 05
We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease

Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?

Dec 15
Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?

Haemonetics Q2 2023 Earnings Preview

Nov 04

Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Oct 04
Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly

Haemonetics: Plasma Thesis Continues To Play Out, Reiterate Buy

Sep 06

Haemonetics reaches new 52-week high; shares up 41% YTD

Aug 24

Haemonetics reports Q2 earnings beat; raises FY22 guidance

Aug 10

A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Aug 10
A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)

Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly

Jul 03
Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly

Earnings and Revenue Growth Forecasts

NYSE:HAE - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/20271,5702723554237
3/31/20261,44122723229810
3/31/20251,39418716823310
9/28/20241,3611243185N/A
6/29/20241,33411569135N/A
3/30/20241,309118115182N/A
12/30/20231,270127129197N/A
9/30/20231,239128199262N/A
7/1/20231,219137176250N/A
4/1/20231,169115163273N/A
12/31/20221,12996128261N/A
10/1/20221,08486116260N/A
7/2/20221,0266888216N/A
4/2/20229934376172N/A
1/1/20229532333106N/A
10/2/20219343154110N/A
7/3/2021903645295N/A
4/3/20218707972109N/A
12/26/2020884108118154N/A
9/26/2020903106120167N/A
6/27/202094696119167N/A
3/28/202098877109158N/A
12/28/20199998081132N/A
9/28/20199886851111N/A
6/29/20199774939139N/A
3/30/20199685540159N/A
12/29/20189524672196N/A
9/29/20189392182204N/A
6/30/201892223N/A205N/A
3/31/201890446N/A220N/A
12/30/2017898-17N/A197N/A
9/30/20178924N/A187N/A
7/1/20178874N/A167N/A
4/1/2017886-26N/A160N/A
12/31/201690016N/A178N/A
10/1/2016906-59N/A155N/A
7/2/2016905-66N/A143N/A
4/2/2016909-56N/A122N/A
12/26/2015893-50N/A124N/A
9/26/201589126N/A119N/A
6/27/201589920N/A123N/A
3/28/201591017N/A127N/A
12/27/201492530N/A123N/A
9/27/201493530N/A142N/A
6/28/201494339N/A140N/A
3/29/201493935N/A140N/A
12/28/201394738N/A116N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HAE's forecast earnings growth (24.3% per year) is above the savings rate (2.6%).

Earnings vs Market: HAE's earnings (24.3% per year) are forecast to grow faster than the US market (15.2% per year).

High Growth Earnings: HAE's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: HAE's revenue (6% per year) is forecast to grow slower than the US market (9.1% per year).

High Growth Revenue: HAE's revenue (6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: HAE's Return on Equity is forecast to be high in 3 years time (28.2%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 03:33
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/28
Annual Earnings2024/03/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Haemonetics Corporation is covered by 29 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Daniel OwczarskiAvondale Partners
Ishan MajumdarBaptista Research
Gary PrestopinoBarrington Research Associates, Inc.